CELU vs. ALLO, JBIO, PBYI, FENC, VOR, EDIT, DBVT, IMMP, ANNX, and VYGR
Should you be buying Celularity stock or one of its competitors? The main competitors of Celularity include Allogene Therapeutics (ALLO), Jade Biosciences (JBIO), Puma Biotechnology (PBYI), Adherex Technologies (FENC), Vor Biopharma (VOR), Editas Medicine (EDIT), DBV Technologies (DBVT), Prima BioMed (IMMP), Annexon (ANNX), and Voyager Therapeutics (VYGR). These companies are all part of the "pharmaceutical products" industry.
Celularity vs. Its Competitors
Allogene Therapeutics (NASDAQ:ALLO) and Celularity (NASDAQ:CELU) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability and analyst recommendations.
83.6% of Allogene Therapeutics shares are owned by institutional investors. Comparatively, 19.0% of Celularity shares are owned by institutional investors. 13.2% of Allogene Therapeutics shares are owned by insiders. Comparatively, 22.1% of Celularity shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Allogene Therapeutics has a net margin of 0.00% compared to Celularity's net margin of -165.22%. Allogene Therapeutics' return on equity of -55.99% beat Celularity's return on equity.
In the previous week, Allogene Therapeutics and Allogene Therapeutics both had 6 articles in the media. Celularity's average media sentiment score of 0.82 beat Allogene Therapeutics' score of 0.81 indicating that Celularity is being referred to more favorably in the news media.
Celularity has higher revenue and earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.
Allogene Therapeutics has a beta of 0.36, suggesting that its stock price is 64% less volatile than the S&P 500. Comparatively, Celularity has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500.
Allogene Therapeutics currently has a consensus price target of $8.44, indicating a potential upside of 647.30%. Celularity has a consensus price target of $6.00, indicating a potential upside of 158.62%. Given Allogene Therapeutics' higher possible upside, equities analysts clearly believe Allogene Therapeutics is more favorable than Celularity.
Summary
Allogene Therapeutics and Celularity tied by winning 7 of the 14 factors compared between the two stocks.
Get Celularity News Delivered to You Automatically
Sign up to receive the latest news and ratings for CELU and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CELU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Celularity Competitors List
Related Companies and Tools
This page (NASDAQ:CELU) was last updated on 9/13/2025 by MarketBeat.com Staff
Free CELU Stock Alerts